Literature DB >> 21637285

The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.

S K Martin1, P Diamond, S Gronthos, D J Peet, A C W Zannettino.   

Abstract

Hypoxia is an imbalance between oxygen supply and demand, which deprives cells or tissues of sufficient oxygen. It is well-established that hypoxia triggers adaptive responses, which contribute to short- and long-term pathologies such as inflammation, cardiovascular disease and cancer. Induced by both microenvironmental hypoxia and genetic mutations, the elevated expression of the hypoxia-inducible transcription factor-1 (HIF-1) and HIF-2 is a key feature of many human cancers and has been shown to promote cellular processes, which facilitate tumor progression. In this review, we discuss the emerging role of hypoxia and the HIFs in the pathogenesis of multiple myeloma (MM), an incurable hematological malignancy of BM PCs, which reside within the hypoxic BM microenvironment. The need for current and future therapeutic interventions to target HIF-1 and HIF-2 in myeloma will also be discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21637285     DOI: 10.1038/leu.2011.122

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  62 in total

1.  Myeloma as a model for the process of metastasis: implications for therapy.

Authors:  Irene M Ghobrial
Journal:  Blood       Date:  2012-04-24       Impact factor: 22.113

2.  The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.

Authors:  Paola Storti; Denise Toscani; Irma Airoldi; Valentina Marchica; Sophie Maiga; Marina Bolzoni; Elena Fiorini; Nicoletta Campanini; Eugenia Martella; Cristina Mancini; Daniela Guasco; Valentina Ferri; Gaetano Donofrio; Franco Aversa; Martine Amiot; Nicola Giuliani
Journal:  Haematologica       Date:  2015-12-11       Impact factor: 9.941

3.  Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.

Authors:  Naoya Mimura; Mariateresa Fulciniti; Gullu Gorgun; Yu-Tzu Tai; Diana Cirstea; Loredana Santo; Yiguo Hu; Claire Fabre; Jiro Minami; Hiroto Ohguchi; Tanyel Kiziltepe; Hiroshi Ikeda; Yutaka Kawano; Maureen French; Martina Blumenthal; Victor Tam; Nathalie L Kertesz; Uriel M Malyankar; Mark Hokenson; Tuan Pham; Qingping Zeng; John B Patterson; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2012-04-26       Impact factor: 22.113

4.  Direct measurement of hypoxia in a xenograft multiple myeloma model by optical-resolution photoacoustic microscopy.

Authors:  Toru Imai; Barbara Muz; Cheng-Hung Yeh; Junjie Yao; Ruiying Zhang; Abdel Kareem Azab; Lihong Wang
Journal:  Cancer Biol Ther       Date:  2017-01-03       Impact factor: 4.742

5.  Hypoxia inducible factor-1 alpha and multiple myeloma.

Authors:  Archana Bhaskar; Bhupendra Nath Tiwary
Journal:  Int J Adv Res (Indore)       Date:  2016-01-01

6.  Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions.

Authors:  Jianguo Wen; Wenjing Tao; Isere Kuiatse; Pei Lin; Yongdong Feng; Richard J Jones; Robert Z Orlowski; Youli Zu
Journal:  Int J Cancer       Date:  2014-07-23       Impact factor: 7.396

7.  Metabolic signature identifies novel targets for drug resistance in multiple myeloma.

Authors:  Patricia Maiso; Daisy Huynh; Michele Moschetta; Antonio Sacco; Yosra Aljawai; Yuji Mishima; John M Asara; Aldo M Roccaro; Alec C Kimmelman; Irene M Ghobrial
Journal:  Cancer Res       Date:  2015-03-13       Impact factor: 12.701

8.  HIF-1α and rapamycin act as gerosuppressant in multiple myeloma cells upon genotoxic stress.

Authors:  Clémence Coudre; Julien Alani; William Ritchie; Véronique Marsaud; Brigitte Sola; Julie Cahu
Journal:  Cell Cycle       Date:  2016-06-24       Impact factor: 4.534

9.  Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1.

Authors:  Teresa S Hawley; Irene Riz; Wenjing Yang; Yoshiyuki Wakabayashi; Louis Depalma; Young-Tae Chang; Weiqun Peng; Jun Zhu; Robert G Hawley
Journal:  Am J Hematol       Date:  2013-03-08       Impact factor: 10.047

Review 10.  Concise review: growth differentiation factor 15 in pathology: a clinical role?

Authors:  Jill Corre; Benjamin Hébraud; Philippe Bourin
Journal:  Stem Cells Transl Med       Date:  2013-11-04       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.